NORD 2014: Rare Diseases & Orphan Products Breakthrough Summit

October 20, 2014

This year’s Breakthrough Summit is the singular time when all stakeholders in the rare disease community meet for an opportunity to discuss collaboration, and to focus on our successes and remaining challenges.

Alexandria, VA  |  Hilton Mark Center

Amy Grogg, President of AmerisourceBergen Consulting Services leads a panel presentation, "The Future Landscape for Commercializing Innovative Rare Disease Therapies." Mary Ann Zamula, SVP, Operations, Lash Group, participates in a panel presentation “Running the Gauntlet - What Patients Have to do to Get Orphan Drug Coverage.”

Running the Gauntlet — What Patients Have to Do to Get Orphan Drug Coverage

  • Patient experience with orphan drug coverage challenges
  • Physician perspective on coverage challenges
  • Payer coverage approaches
  • Interactions with Hubs and patient assistance programs
  • Current challenges and opportunities for access in the exchanges

Moderator

Pamela Gavin
Chief Operating Officer
NORD

Panelists

Larry LaMotte
Vice President of Advocacy
Immune Deficiency Foundation

Mary Ann Zamula
SVP, Strategic Account Management
Lash Group


The Future Landscape for Commercializing Innovative Rare Disease Therapies

  • Access and reimbursement — What does the future look like?
  • How will companion products change the landscape?
  • What insights can we glean from orphan therapy coverage models across the globe?
  • How could access and reimbursement trends impact innovation?

Moderator

Amy Grogg, PharmD
President
AmerisourceBergen Consulting Services

Panelists

Donald Han
Vice President, Payer Insights and Access
Pfizer, Inc.

Ruth Suter
Director of Market Access
BioMarin

Eric Mosbrooker
Dir. of Market Access
Raptor Pharmaceuticals